RCT and "Mathematical Embellishment"
|
|
2
|
2807
|
April 5, 2022
|
Chi-Squared for relative risk
|
|
1
|
1897
|
March 27, 2022
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
9
|
2829
|
March 25, 2022
|
How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
1625
|
March 6, 2022
|
Covariate imbalance in RCT
|
|
5
|
3597
|
February 23, 2022
|
Estimate treatment effect in study with a composite complication score as outcome
|
|
9
|
2059
|
February 18, 2022
|
Single cluster cluster randomized crossover (CRXO) design?
|
|
3
|
1703
|
February 17, 2022
|
Bernoulli trials vs completely randomized trials
|
|
0
|
1624
|
January 5, 2022
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
1552
|
December 28, 2021
|
Cost-effectiveness based interim analysis
|
|
2
|
2455
|
December 15, 2021
|
Interpretation of the REGEN-COV trial
|
|
22
|
9752
|
November 1, 2021
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
16176
|
October 8, 2021
|
Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
2641
|
September 2, 2021
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
2774
|
August 8, 2021
|
Heterogeneity in RCTs with continuous outcome
|
|
19
|
8322
|
July 2, 2021
|
Default Using R package to implement Bayesian phase I/II dose-finding design for three outcomes
|
|
10
|
3059
|
June 10, 2021
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
4217
|
December 30, 2020
|
RCT trials for COVID study vaccines
|
|
0
|
2957
|
October 24, 2020
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
2824
|
October 13, 2020
|
"Open label, double-masked trial"
|
|
0
|
3093
|
October 13, 2020
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
2828
|
September 30, 2020
|
Time since randomization and causality
|
|
2
|
2169
|
September 27, 2020
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
4803
|
September 22, 2020
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
4820
|
August 11, 2020
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
2759
|
August 11, 2020
|
MERINO trial - adjusting for infection source
|
|
3
|
4540
|
August 3, 2020
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
3563
|
July 19, 2020
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
4169
|
June 15, 2020
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
2900
|
May 15, 2020
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
3404
|
March 11, 2020
|